Ladenburg analyst Aydin Huseynov kept a Buy rating on Cellectar Biosciences (CLRB) with a $13 price target following a transfer in coverage. Cellectar is expected to file a new drug application in December for its lead drug candidate iopofosine in relapsed/refractory Waldenstrom’s macroglobulinemia patients who had at least two prior lines of therapy, the analyst tells investors in a research note. The firm expects a “smooth NDA process” with expedited FDA approval in mid-2025 and launch of iopofosine in Q4 of next year.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLRB:
- Cellectar Biosciences price target lowered to $12 from $14 at Oppenheimer
- Cellectar Biosciences Reports Q3 2024 Financial Results
- Cellectar Biosciences reports Q3 EPS (40c), consensus (37c)
- Cellectar Biosciences sees cash runway into 2Q25
- Options Volatility and Implied Earnings Moves Today, November 18, 2024
Questions or Comments about the article? Write to editor@tipranks.com